ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.

Guideline ID: 3497 Published: 2023 Jan

European Alliance of Associations for Rheumatology (EULAR) | Assessment of SpondyloArthritis International Society (ASAS)

Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34. [156 references] PubMed

View Original Guideline

Overview

Guideline Objective

To update the ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA)

Patient Population

Patients with axSpA

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Over-arching management principles
- Role of disease monitoring and patient education
- Guidance on use of pharmacotherapy, including non-steroidal anti-inflammatory drug (NSAIDs), analgesics, glucocorticoid injections, conventional synthetic disease-modifying antirheumatic drug (csDMARDs), and biological DMARDs (bDMARDs)
- Indications for total hip arthroplasty and further disease evaluation
- Consideration of comorbidities

Note: Refer to the original guideline for full recommendation statements.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis; 2023 Jan.
- Efficacy and Safety of Non-pharmacological and Non-biological Interventions: A Systematic Literature Review Informing the 2022 Update of the ASAS/EULAR Recommendations for the Management of Axial Spondyloarthritis; 2023 Jan.

Implementation Tools

- The Original Guideline includes the following:
    - Figure 1. Algorithm Based on the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis (axSpA) (p. 5)

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

TRUST Scorecard

Composition of Guideline Development Group (GDG)

Multidisciplinary GDG Members	**No**
Methodologist Involvement	**Yes**
Incorporation of Patient and Public Perspective	

Systematic Review of Evidence

Literature Search	
Study Selection	
Evidence Synthesis	

Foundations for Recommendations

Strength of Evidence Grade	
Description of Benefits and Harms of Recommendations	
Summary of Evidence Supporting Recommendations	
Strength of Recommendations Rating	
Clear Articulation of Recommendations	

Funding Source

Yes

Disclosure and Management of Financial Conflicts of Interests



External Review



Updating



Copyright © 2025 ECRI